Current status and evolution of preclinical drug development models of epithelial ovarian cancer

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Konstantinopoulos, Panagiotis A ^a   Matulonis, Ursula A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell lines; Epithelial ovarian cancer; High grade serous; Mouse models; Patient derived xenografts; Personalized therapy; Preclinical models; Xenografts

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; ABAGOVOMAB; BEVACIZUMAB; OLAPARIB; OREGOVOMAB; PACLITAXEL; PERTUZUMAB; PROTEIN P53; RAPAMYCIN; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER SURVIVAL; COPY NUMBER VARIATION; DRUG DESIGN; GENETICALLY ENGINEERED MOUSE STRAIN; HISTOLOGY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; RNA INTERFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC ORGANISM; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

EID: 84892377231     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00296     Document Type: Review

References (113)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166.
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354:34-43. doi:10.1056/NEJMoa052985.
3. Konstantinopoulos PA, Awtrey CS. Management of ovarian cancer: a 75-year-old woman who has completed treatment. JAMA (2012) 307:1420-9. doi:10.1001/jama.2012.269.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 334:1-6. doi:10.1056/NEJM199601043340101.
5. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2007) 25:3621-7. doi:10.1200/JCO.2006.10.2517.
6. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol (2009) 4:287-313. doi:10.1146/annurev.pathol.4.110807.092246.
7. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 24:1053-65. doi:10.1038/sj.onc.1208298.
8. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 164:1511-8. doi:10.1016/S0002-9440(10)63708-X.
9. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 363:1532-43. doi:10.1056/NEJMoa1008433.
10. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474:609-15.
11. Stein WD, Litman T, Fojo T, Bates SE. A serial analysis of gene expression (sage) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res (2004) 64:2805-16. doi:10.1158/0008-5472.CAN-03-3383.
12. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 108:18708-13. doi:10.1073/pnas.1111840108.
13. Sandberg R, Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci U S A (2005) 102:2052-7. doi:10.1073/pnas.0408105102.
14. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4:2126. doi:10.1038/ncomms3126.
15. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 17:6083-96. doi:10.1158/1078-0432.CCR-11-0945.
16. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 483:603-7. doi:10.1038/nature11003.
17. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-21. doi:10.1038/nature03445.
18. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361:123-34. doi:10.1056/NEJMoa0900212.
19. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFS). Exp Cell Res (1995) 218:499-507. doi:10.1006/excr.1995.1184.
20. Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol (1992) 167:729-35. doi:10.1016/S0002-9378(11)91579-8.
21. Li NF, Kocher HM, Salako MA, Obermueller E, Sandle J, Balkwill F. A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells. Oncogene (2009) 28:773-80. doi:10.1038/onc.2008.412.
22. Davies BR, Steele IA, Edmondson RJ, Zwolinski SA, Saretzki G, von Zglinicki T, et al. Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen. Exp Cell Res (2003) 288:390-402. doi:10.1016/S0014-4827(03)00218-0.
23. Yang G, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene (2007) 26:1492-8. doi:10.1038/sj.onc.1209905.
24. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr., et al. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis (2007) 28:174-82. doi:10.1093/carcin/bgl115.
25. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 108:7547-52. doi:10.1073/pnas.1017300108.
26. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 13:899-911.
27. Shan W, Mercado-Uribe I, Zhang J, Rosen D, Zhang S, Wei J, et al. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 11:2107-13. doi:10.4161/cc.20544.
28. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci (Landmark Ed) (2011) 16:368-92. doi:10.2741/3693.
29. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 68:4311-20. doi:10.1158/0008-5472.CAN-08-0364.
30. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells (2009) 27:2405-13. doi:10.1002/stem.191.
31. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. Cd24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene (2010) 29:2672-80. doi:10.1038/onc.2010.35.
32. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 495:241-5. doi:10.1038/nature11979.
33. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res (1984) 44:5286-90.
34. Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol (1992) 30:43-50. doi:10.1007/BF00686484.
35. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer (1989) 44:494-500. doi:10.1002/ijc.2910440320.
36. Ward BG, Wallace K. Localization of the monoclonal antibody hmfg2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res (1987) 47:4714-8.
37. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 174:6477-89.
38. Molthoff CF, Calame JJ, Pinedo HM, Boven E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer (1991) 47:72-9. doi:10.1002/ijc.2910470114.
39. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther (2004) 10:1032-42. doi:10.1016/j.ymthe.2004.08.013.
40. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 43:5379-89.
41. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol (2002) 161:1917-24. doi:10.1016/S0002-9440(10)64467-7.
42. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-4. doi:10.1038/362841a0.
43. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol (2007) 25:5165-71. doi:10.1200/JCO.2007.11.5345.
44. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 25:5180-6. doi:10.1200/JCO.2007.12.0782.
45. Shaw D, Clamp A, Jayson GC. Angiogenesis as a target for the treatment of ovarian cancer. Curr Opin Oncol (2013) 25:558-65. doi:10.1097/CCO.0b013e328363e0da.
46. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res (1993) 13:283-6.
47. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst (2002) 94:522-8. doi:10.1093/jnci/94.7.522.
48. Connolly DC. Animal models of ovarian cancer. Cancer Treat Res (2009) 149:353-91. doi:10.1007/978-0-387-98094-2_17.
49. Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer. Reprod Biol Endocrinol (2003) 1:67. doi:10.1186/1477-7827-1-67.
50. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res (2006) 12:5277-87. doi:10.1158/1078-0432.CCR-06-0436.
51. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 9:338-50. doi:10.1038/nrclinonc.2012.61.
52. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol (2010) 12:473-80. doi:10.1007/s12094-010-0540-6.
53. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2:247-50. doi:10.1038/nprot.2007.25.
54. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther (2009) 85:217-21. doi:10.1038/clpt.2008.200.
55. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res (2006) 66:3351-4. discussion 3354, doi:10.1158/0008-5472.CAN-05-3627.
56. Huang S, Pan W, Zhang J, Zhao B, Wang H, Liu F, et al. Heterogeneity-related anticancer therapy response differences in metastatic colon carcinoma: new hints to tumor-site-based personalized cancer therapy. Hepatogastroenterology (2013). doi:10.5754/hge13457.
57. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 135:415-32. doi:10.1007/s10549-012-2164-8.
58. Yang M, Shan B, Li Q, Song X, Cai J, Deng J, et al. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients. Int J Cancer (2013) 132:E74-84. doi:10.1002/ijc.27813.
59. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, et al. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2012) 19(Suppl 3):S395-403. doi:10.1245/s10434-011-1839-4.
60. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 10:1311-6. doi:10.1158/1535-7163.MCT-11-0233.
61. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res (2008) 14:6456-68. doi:10.1158/1078-0432.CCR-08-0138.
62. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 12:4652-61. doi:10.1158/1078-0432.CCR-06-0113.
63. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic mullerian cancers. Clin Cancer Res (2003) 9:845-52.
64. Schmidt KF, Ziu M, Schmidt NO, Vaghasia P, Cargioli TG, Doshi S, et al. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol (2004) 68:207-15. doi:10.1023/B:NEON.0000033364.43142.bf.
65. Verstijnen CP, Arends JW, Moerkerk P, Schutte B, van der Linden E, Kuypers-Engelen B, et al. Culturing and xenografting of primary colorectal carcinoma cells: comparison of in vitro, and in vivo model and primary tumor. Anticancer Res (1988) 8:1193-200.
66. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 14:R11. doi:10.1186/bcr3095.
67. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 69:3364-73. doi:10.1158/0008-5472.CAN-08-4210.
68. Sanz L, Cuesta AM, Salas C, Corbacho C, Bellas C, Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest (2009) 89:91-7. doi:10.1038/labinvest.2008.108.
69. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK Jr., et al. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res (2004) 64:1712-21. doi:10.1158/0008-5472.CAN-03-2700.
70. Grisanzio C, Seeley A, Chang M, Collins M, Di Napoli A, Cheng SC, et al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol (2011) 225:212-21. doi:10.1002/path.2929.
71. Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, et al. Direct orthotopic transplantation of fresh surgical specimen preserves cd133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells (2008) 26:1414-24. doi:10.1634/stemcells.2007-1009.
72. Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol (2010) 12:580-94. doi:10.1093/neuonc/nop056.
73. James CD. Tumor-initiating cells: an influential paradigm for xenograft research. Neuro Oncol (2010) 12:519. doi:10.1093/neuonc/noq053.
74. Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest (2013) 93:970-82. doi:10.1038/labinvest.2013.92.
75. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res (2012) 18:5160-2. doi:10.1158/1078-0432.CCR-12-2408.
76. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in nod/scid/il2 receptor {gamma} chain(null) mice. Blood (2005) 106:1565-73. doi:10.1182/blood-2005-02-0516.
77. Kolfschoten GM, Pinedo HM, Scheffer PG, Schluper HM, Erkelens CA, Boven E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol (2000) 76:362-8. doi:10.1006/gyno.1999.5689.
78. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect (1987) 73:35-51. doi:10.1289/ehp.877335.
79. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig (1998) 5:271-6. doi:10.1016/S1071-5576(98)00017-3.
80. Brewer M, Baze W, Hill L, Utzinger U, Wharton JT, Follen M, et al. Rhesus macaque model for ovarian cancer chemoprevention. Comp Med (2001) 51:424-9.
81. Hsieh FY, Tengstrand E, Lee JW, Li LY, Silverman L, Riordan B, et al. Drug safety evaluation through biomarker analysis-a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer. Toxicol Appl Pharmacol (2007) 224:12-8. doi:10.1016/j.taap.2007.06.009.
82. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAB-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 7:20.
83. Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, et al. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res (2004) 64:8177-83. doi:10.1158/0008-5472.CAN-04-1702.
84. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol (2011) 6:95-119. doi:10.1146/annurev.pathol.3.121806.154244.
85. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 1:53-62. doi:10.1016/S1535-6108(01)00002-2.
86. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res (2006) 66:8949-53. doi:10.1158/0008-5472.CAN-06-1495.
87. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 63:1389-97.
88. Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther (2007) 6:1717-25. doi:10.4161/cbt.6.11.4830.
89. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. Rad001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 67:2408-13. doi:10.1158/0008-5472.CAN-06-4490.
90. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and rb1 in the mouse ovarian surface epithelium. Cancer Res (2003) 63:3459-63.
91. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2005) 11:63-70. doi:10.1038/nm1173.
92. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell (2007) 11:321-33. doi:10.1016/j.ccr.2007.02.016.
93. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 122:553-7. doi:10.1172/JCI59309.
94. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 109:3921-6. doi:10.1073/pnas.1117135109.
95. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 19:3-9. doi:10.1097/GCO.0b013e328011a21f.
96. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 153:1249-56. doi:10.1016/S0002-9440(10)65669-6.
97. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 365:2473-83. doi:10.1056/NEJMoa1104390.
98. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 365:2484-96. doi:10.1056/NEJMoa1103799.
99. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443.
100. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res (2009) 69:3850-5. doi:10.1158/0008-5472.CAN-08-2388.
101. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of brca1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 105:17079-84. doi:10.1073/pnas.0806092105.
102. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res (2010) 17:783-91. doi:10.1158/1078-0432.CCR-10-1382.
103. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376:245-51. doi:10.1016/S0140-6736(10)60893-8.
104. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 28:2512-9. doi:10.1200/JCO.2009.26.9589.
105. Schultes BC, Zhang C, Xue LY, Noujaim AA, Madiyalakan R. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. Hybridoma (1999) 18:47-55. doi:10.1089/hyb.1999.18.47.
106. Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, et al. Abagovomab for ovarian cancer. Expert Opin Biol Ther (2011) 11:395-403. doi:10.1517/14712598.2011.553598.
107. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J Clin Oncol (2013) 31:1554-61. doi:10.1200/JCO.2012.46.4057.
108. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol (2009) 27:418-25. doi:10.1200/JCO.2008.17.8400.
109. Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol (2005) 16:1889-97. doi:10.1093/annonc/mdi405.
110. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer (2005) 104:2701-8. doi:10.1002/cncr.21533.
111. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol (2003) 21:283-90. doi:10.1200/JCO.2003.10.104.
112. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 24:4324-32. doi:10.1200/JCO.2005.05.4221.
113. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 28:1215-23. doi:10.1200/JCO.2009.22.3354.